Qiagen NV

Most Recent

  • uploads///puzzle _
    Company & Industry Overviews

    Why Is Pacific Biosciences Stock Up ~6.2% Today?

    Today, Pacific Biosciences of California (PACB) is trading at $5.16 per share, up ~6.17% from yesterday’s close of $4.86.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Vectra DA Could Be Solid Growth Driver for Myriad Genetics in 2018

    In the first quarter of fiscal 2018, Myriad Genetics’ (MYGN) Vectra DA test reported revenues close to $16 million.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Myriad Genetics Saw Positive Results from GeneSight Trial

    Myriad Genetics (MYGN) announced positive results from its Impact study, which evaluated the effectiveness of the GeneSight precision medicine test.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Myriad Genetics’ GeneSight: A Major Growth Driver in 2018?

    In the first quarter of fiscal 2018, Myriad Genetics’ (MYGN) GeneSight reported revenues of $28.8 million, which is a YoY growth of 54% and a sequential growth of 12%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    BRACAnalysis CDx Received FDA Approval for Ovarian Cancer Indication

    On March 27, 2017, the FDA also approved BRACAnalysis CDX test as a complementary diagnostic test to be used with ovarian cancer maintenance therapy Tesaro’s (TSRO) Zejula (miraparib).

    By Margaret Patrick
  • uploads///Part  Graph
    Company & Industry Overviews

    IBB Holdings: How Are Their Moving Averages Trending?

    The iShares Nasdaq Biotechnology ETF (IBB) has 189 stocks in its portfolio. As of June 6, 2016, 87% of IBB’s stocks were trading above their 20-day moving averages.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    What Are IBB’s Holdings’ Moving Averages?

    On May 27, 2016, 17% of the iShares Nasdaq Biotechnology ETF’s (IBB) stocks were trading above their 20-day moving averages.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Grifols Maintains Its Dividend Payout at 40%

    Grifols (GRFS) outperformed other international securities within IBB with a return of 8.5% for the week ending May 27 as it announced a dividend payment.

    By Peter Neil
  • uploads/uploads///Vanguard Capital Opportunity Fund %E%% Investor Shares Vs Peers
    Company & Industry Overviews

    Options for Investors in the Vanguard Capital Opportunity Fund

    From a purely NAV (net asset value) return standpoint, the Vanguard Capital Opportunity Fund has had a forgettable one-year period until March 18, 2016, as it stood tenth among its peer group.

    By David Ashworth
  • uploads///Graph Part
    Company & Industry Overviews

    Dyax Traded above Its 100-Day Moving Average

    Dyax (DYAX) gained 9.41% last week. The stock went up after Dyax presented at the Morgan Stanley global healthcare conference, which took place September 16-18 in New York.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    IBB ADRs Outperform Benchmark for August 10–17, 2015

    The iShares NASDAQ Biotechnology ETF (IBB) has 14 American Depository Receipts (ADR) in its portfolio. These ADRs have a weight of 9.36% and gave an average return of 0.85% for August 10–17, 2015.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Healthcare and Pharmaceuticals Prevail in Stable Market Conditions

    The healthcare sector and the pharmaceutical sector underperformed IBB, but outperformed the broader index SPY for the week ending July 31, 2015.

    By Peter Neil
  • uploads///Part
    Company & Industry Overviews

    Biotech ETF Provides Exposure to International Stocks

    The iShares Nasdaq Biotechnology ETF (IBB) has exposure to 14 international stocks, with a weight of 9.36%. For the week ended July 24, the average return of these shares was -2.13%.

    By Peter Neil
  • uploads///Part
    Company & Industry Overviews

    Biogen Stock Fell for the Week Ending July 24

    For the week ending July 24, 2015, Biogen (BIIB) stock fell by -25.86%. The stock fell based on the downward revision of its 2015 revenue.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.